ArticleJournal for immunotherapy of cancer2025

Anti-HER2×CCR4 bispecific antibody enhances antitumor immunity in advanced HER2-positive tumors by chemotaxis blockade and depletion of tumor-associated Tregs, without inducing systemic toxicity.

Chaokun Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.